News from WCM

A team of Weill Cornell Medicine investigators has developed a computer model that will help scientists more efficiently develop protein-destroying therapies, a newer type of treatment that is particularly promising for cancer.

Weill Cornell Medicine investigators have discovered specific mechanisms that enable the bacteria not only to survive drying but also to generate mutations linked to antibiotic resistance. 

Weill Cornell Medicine investigators have developed a set of molecular tools to regulate the activity of specific genes in one of the most common classes of intestinal bacteria. 

On Aug. 18, 106 first-year medical students in the Class of 2030 earned their white coats during the annual White Coat Ceremony, officially marking the beginning of their medical education. 

Fifty physician assistant students donned their white coats Aug. 18 during the annual White Coat Ceremony—the first time PA students attained this milestone on the same day as medical students. 

Prostate tumors can rewire amino acid metabolism to override the normal brakes on cholesterol production, a process that may fuel hormone therapy resistance, according to a study by Weill Cornell Medicine investigators.

A conceptual framework like the one engineers use for characterizing the transmission of sound and electrical signals can be useful in studying how olfaction—the sense of smell—is influenced by the air flow that carries odor molecules, according to a study led by investigators at Weill Cornell Medicine and the University of Colorado—Boulder.

Traumatic brain injury (TBI) in Pakistan is associated with a high risk of death and disability long after the initial injury, even in mild to moderate cases, according to two new studies in JAMA Network Open led by Weill Cornell Medicine researchers.

Brain-resident immune cells that have reached an old-age state called senescence secrete a protein that causes dysfunction in other brain cells, according to a study led by investigators at Weill Cornell Medicine. 

Researchers at Weill Cornell Medicine have uncovered how a key Parkinson's protein called LRRK2 shifts between inactive and active forms, revealing the structural changes that enable certain mutations to push the protein into an overactive state. 

Artificial intelligence may enhance implementation of a new federal rule requiring aduts enrolled under the Affordable Care Act expansion of Medicaid eligibility to complete qualifying work hours or community engagement activities or meet exemption criteria to maintain coverage, according to a new commentary.

Earlier use of a targeted radionuclide therapy delays metastatic prostate cancer progression when administered as part of a trio of drugs, according to a phase 3 clinical trial led by Weill Cornell Medicine, NewYork-Presbyterian, Memorial Sloan Kettering Cancer Center and investigators at several other institutions worldwide.

During development, regional dips in oxygen levels serve as a signal that triggers the coordinated growth of heart muscle and coronary vessels, according to a new study. 

A protein that can dial down oxidative stress in cells helps some cancers resist treatment with a widely used class of drugs called BTK inhibitors, according to a study led by investigators at Weill Cornell Medicine. 

A protein secreted by common cancer types makes blood vessels leakier to allow metastatic tumors to form in the lungs, according to a study led by investigators at Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center.

An overactive immune response in the brain may play a role in Dravet Syndrome, a rare and severe genetic epilepsy that typically begins in infancy, according to Weill Cornell Medicine researchers. 

Weill Cornell Medicine investigators have developed a new AI-based method to assess patients with a form of blood cancer called myelodysplastic neoplasms.

Dr. Imperato-McGinley, esteemed endocrinologist, looks back at her 50-year career as a pioneer in her field and leader of the translational research enterprise at Weill Cornell Medicine. 

Weill Cornell Medicine has received a $2.5 million, three-year grant from the Department of Defense (DoD) to develop therapies with fewer side effects for triple-negative breast cancer, one of the most aggressive and difficult-to-treat breast cancers. 

Significant advances have been made in the development of patient-derived tumor organoids for preclinical research, in two new studies led by Weill Cornell Medicine investigators.